Skip to content
DataLookout
Menu

NCT02648997

An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma

StatusActive, Not Recruiting
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 19 versions: 18 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 92 words
    • Study completion pushed from Oct 1, 2026 to Apr 1, 2027
    • Interventions: External Beam RT (Radiation), Ipilimumab - 1 mg/kg (Drug), Ipilimumab - 3 mg/kg (Drug), Nivolumab - 1 mg/kg (Drug), Nivolumab - 240 mg… to External Beam RT (Radiation), Ipilimumab - 1 mg/kg (Drug), Ipilimumab - 3 mg/kg (Drug), Nivolumab - 1 mg/kg (Drug), Nivolumab - 240 mg…
    • Secondary endpoints: details revised at 4 of 4 entries
  2. Minor Study completion pushed from Jun 1, 2026 to Oct 1, 2026v18
  3. Notable Results first posted: Jan 26, 2026v17 Show 5 more changesShow less
    • Primary endpoint revised
    • Study completion date: Dec 1, 2025 to Jun 1, 2026
    • Interventions: External Beam RT (Radiation), Ipilimumab - 1 mg/kg (Drug), Nivolumab - 240 mg (Drug), Nivolumab - 3 mg/kg (Drug), Nivolumab - 480 mg (Drug) to External Beam RT (Radiation), Ipilimumab - 1 mg/kg (Drug), Ipilimumab - 3 mg/kg (Drug), Nivolumab - 1 mg/kg (Drug), Nivolumab - 240 mg…
    • Secondary endpoints revised (4)
    • Study arms: 2 to 3
  4. Minor Trial status: Recruiting to Active, Not Recruitingv15 Show 5 more changesShow less
    • Enrollment target: estimated 50 to confirmed 40
    • Primary completion date: Mar 2025 to Dec 1, 2024
    • Study completion date: Sep 2025 to Dec 1, 2025
    • Site details revised
    • Study title expanded, about 2 words
  5. Notable Primary completion date: Dec 2023 to Mar 2025
    • Study completion date: Jun 2024 to Sep 2025
    v14
Show 12 earlier versionsHide 12 earlier versions
  1. Notable Eligibility criteria expanded, about 5 wordsv13 Show 4 more changesShow less
    • Primary completion date: Jun 2023 to Dec 2023
    • Study completion date: Dec 2023 to Jun 2024
    • Secondary endpoints: details revised at 4 of 4 entries
    • Study title revised
  2. Notable Primary completion date: Oct 2021 to Jun 2023
    • Study completion date: Dec 2022 to Dec 2023
    v12
  3. Notable Primary completion date: Feb 2021 to Oct 2021
    • Study completion date: Apr 2022 to Dec 2022
    v11
  4. Notable Trial status: Active, Not Recruiting to Recruiting
    • Interventions: External Beam RT (Radiation), Ipilimumab - 3 mg/kg (Drug), Nivolumab - 1 mg/kg (Drug), Nivolumab - 240 mg (Drug), Nivolumab - 480 mg (Drug) to External Beam RT (Radiation), Ipilimumab - 1 mg/kg (Drug), Nivolumab - 240 mg (Drug), Nivolumab - 3 mg/kg (Drug), Nivolumab - 480 mg (Drug)
    • Site details revised
    v10
  5. Minor Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v9
  6. Notable Primary completion date: Feb 2020 to Feb 2021
    • Study completion date: Apr 2021 to Apr 2022
    v8
  7. Notable Enrollment target: 25 to 50v7 Show 10 more changesShow less
    • Primary completion date: Apr 2019 to Feb 2020
    • Eligibility criteria expanded, about 120 words
    • Primary endpoint revised
    • Study completion date: Apr 2020 to Apr 2021
    • Interventions: Nivolumab (Drug) to External Beam RT (Radiation), Ipilimumab - 3 mg/kg (Drug), Nivolumab - 1 mg/kg (Drug), Nivolumab - 240 mg (Drug), Nivolumab - 480 mg (Drug)
    • Secondary endpoints revised (4)
    • Study description expanded, about 38 words
    • Study arms: 1 to 2
    • Collaborators expanded, about 2 words
    • Study title expanded, about 3 words
  8. Notable Primary completion date: Aug 2018 to Apr 2019
    • Study completion date: Dec 2019 to Apr 2020
    v6
  9. Minor Primary completion date: Jul 2019 to Aug 2018
    • Study completion date: Jul 2023 to Dec 2019
    v5
  10. Notable Eligibility criteria expanded, about 9 words
    • Secondary endpoints: 3 to 4
    • Study description revised
    v4
  11. Notable Eligibility criteria revisedv3
  12. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 2 to 1
    • Start date: Feb 2016 to Mar 2016
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Number of Participants Without Disease Progression At Six Months Following Initiation Of Study Therapy
Timeframe: 6 months

Secondary (4)

Both Cohorts: Median Progression-Free Survival
Both Cohorts: Median Overall Survival
Both Cohorts: Objective Radiologic Response Rate
Both Cohorts: Number of Participants With Treatment Related Adverse Events as Assessed by CTCAE v4.0.

Arms and interventions

Cohort 1 (original cohort): Nivolumab MonotherapyExperimental

Nivolumab monotherapy (240 mg every 2 weeks)

Cohort 2 (Dose Level 0): Nivolumab in Combination with IpilimumabExperimental

* External Beam RT (IMRT, 3D-CRT, or proton-beam radiation therapy) * Followed by 4 cycles of Nivolumab (1 mg/kg every 3 weeks) + Ipilimumab (3 mg/kg every 3 weeks) * Followed by Nivolumab monotherapy (480 mg every 4 weeks).

Cohort 2 (Dose Level 0A): Nivolumab in Combination with IpilimumabExperimental

* External Beam RT (IMRT, 3D-CRT, or proton-beam radiation therapy) * Followed by 4 cycles of Nivolumab (3 mg/kg every 3 weeks) + Ipilimumab (1 mg/kg every 3 weeks) * Followed by Nivolumab monotherapy (480 mg every 4 weeks).

Drugs: Nivolumab - 240 mg, Ipilimumab - 1 mg/kg, Nivolumab - 480 mg, Nivolumab - 3 mg/kg, Nivolumab - 1 mg/kg, Ipilimumab - 3 mg/kg

Radiation: External Beam RT

Sites

1 site in 1 country

  • Dana-Farber Cancer InstituteBoston, Massachusetts, United States